200 related articles for article (PubMed ID: 36048256)
1. Molecular docking, synthesis, and biological evaluation of 7-azaindole-derivative (7AID) as novel anti-cancer agent and potent DDX3 inhibitor:-an in silico and in vitro approach.
Doneti R; Pasha A; Botlagunta M; Heena SK; Mutyala VVVP; Pawar SC
Med Oncol; 2022 Sep; 39(11):179. PubMed ID: 36048256
[TBL] [Abstract][Full Text] [Related]
2. A Computational Approach with Biological Evaluation: Combinatorial Treatment of Curcumin and Exemestane Synergistically Regulates DDX3 Expression in Cancer Cell Lines.
Rampogu S; Kim SM; Son M; Baek A; Park C; Lee G; Kim Y; Kim GS; Kim JH; Lee KW
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32512851
[TBL] [Abstract][Full Text] [Related]
3. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.
Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
[TBL] [Abstract][Full Text] [Related]
4. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer.
Samal SK; Routray S; Veeramachaneni GK; Dash R; Botlagunta M
Sci Rep; 2015 Apr; 5():9982. PubMed ID: 25918862
[TBL] [Abstract][Full Text] [Related]
5. Identification of the DEAD box RNA helicase DDX3 as a therapeutic target in colorectal cancer.
Heerma van Voss MR; Vesuna F; Trumpi K; Brilliant J; Berlinicke C; de Leng W; Kranenburg O; Offerhaus GJ; Bürger H; van der Wall E; van Diest PJ; Raman V
Oncotarget; 2015 Sep; 6(29):28312-26. PubMed ID: 26311743
[TBL] [Abstract][Full Text] [Related]
6. DDX3, a potential target for cancer treatment.
Bol GM; Xie M; Raman V
Mol Cancer; 2015 Nov; 14():188. PubMed ID: 26541825
[TBL] [Abstract][Full Text] [Related]
7. DDX3, a DEAD box RNA helicase with tumor growth-suppressive property and transcriptional regulation activity of the p21waf1/cip1 promoter, is a candidate tumor suppressor.
Chao CH; Chen CM; Cheng PL; Shih JW; Tsou AP; Lee YH
Cancer Res; 2006 Jul; 66(13):6579-88. PubMed ID: 16818630
[TBL] [Abstract][Full Text] [Related]
8. In vitro anti-cancer activity of doxorubicin against human RNA helicase, DDX3.
Botlagunta M; Kollapalli B; Kakarla L; Gajarla SP; Gade SP; Dadi CL; Penumadu A; Javeed S
Bioinformation; 2016; 12(7):347-353. PubMed ID: 28246464
[TBL] [Abstract][Full Text] [Related]
9. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.
Wilky BA; Kim C; McCarty G; Montgomery EA; Kammers K; DeVine LR; Cole RN; Raman V; Loeb DM
Oncogene; 2016 May; 35(20):2574-83. PubMed ID: 26364611
[TBL] [Abstract][Full Text] [Related]
10. Novel Butein Derivatives Repress DDX3 Expression by Inhibiting PI3K/AKT Signaling Pathway in MCF-7 and MDA-MB-231 Cell Lines.
Rampogu S; Kim SM; Shaik B; Lee G; Kim JH; Kim GS; Lee KW; Kim MO
Front Oncol; 2021; 11():712824. PubMed ID: 34485148
[TBL] [Abstract][Full Text] [Related]
11. Regulation of p21 expression for anti-apoptotic activity of DDX3 against sanguinarine-induced cell death on intrinsic pathway.
Nguyen CN; Nguyen KVA; Eom S; Choi YJ; Kang LJ; Lee J; Kim C; Lee S; Lee SG; Lee JH
Phytomedicine; 2019 Dec; 65():153096. PubMed ID: 31568920
[TBL] [Abstract][Full Text] [Related]
12. DEAD-box RNA Helicase DDX3: Functional Properties and Development of DDX3 Inhibitors as Antiviral and Anticancer Drugs.
Kukhanova MK; Karpenko IL; Ivanov AV
Molecules; 2020 Feb; 25(4):. PubMed ID: 32102413
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic role of DDX3 in breast cancer biogenesis.
Botlagunta M; Vesuna F; Mironchik Y; Raman A; Lisok A; Winnard P; Mukadam S; Van Diest P; Chen JH; Farabaugh P; Patel AH; Raman V
Oncogene; 2008 Jun; 27(28):3912-22. PubMed ID: 18264132
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of novel combretastatin analogues of 1,1-diaryl vinyl sulfones, with antiproliferative potential via in-silico and in-vitro studies.
Egharevba GO; Kamal A; Dosumu OO; Routhu S; Fadare OA; Oguntoye SO; Njinga SN; Oluyori AP
Sci Rep; 2022 Feb; 12(1):1901. PubMed ID: 35115623
[TBL] [Abstract][Full Text] [Related]
15. DDX3 modulates cell adhesion and motility and cancer cell metastasis via Rac1-mediated signaling pathway.
Chen HH; Yu HI; Cho WC; Tarn WY
Oncogene; 2015 May; 34(21):2790-800. PubMed ID: 25043297
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
17. DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids.
Wang H; Kim S; Ryu WS
J Virol; 2009 Jun; 83(11):5815-24. PubMed ID: 19297497
[TBL] [Abstract][Full Text] [Related]
18. Ezrin Binds to DEAD-Box RNA Helicase DDX3 and Regulates Its Function and Protein Level.
Çelik H; Sajwan KP; Selvanathan SP; Marsh BJ; Pai AV; Kont YS; Han J; Minas TZ; Rahim S; Erkizan HV; Toretsky JA; Üren A
Mol Cell Biol; 2015 Sep; 35(18):3145-62. PubMed ID: 26149384
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of DDX3 and COX-2 by forskolin and evaluation of anti-proliferative, pro-apoptotic effects on cervical cancer cells: molecular modelling and in vitro approaches.
Ravinder D; Rampogu S; Dharmapuri G; Pasha A; Lee KW; Pawar SC
Med Oncol; 2022 Apr; 39(5):61. PubMed ID: 35478276
[TBL] [Abstract][Full Text] [Related]
20. The DEAD-box RNA helicase DDX3 interacts with DDX5, co-localizes with it in the cytoplasm during the G2/M phase of the cycle, and affects its shuttling during mRNP export.
Choi YJ; Lee SG
J Cell Biochem; 2012 Mar; 113(3):985-96. PubMed ID: 22034099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
